Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

MPLX LP (MPLX) closed the most recent trading day at $56.58, moving +1.09% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.06%. Meanwhile, the ...

Very high Lp(a) also correlated with higher risks of ischemic stroke and cardiovascular mortality in the Women’s Health Study ...

Lipoprotein(a) levels, which are largely determined by genetics, appear to fluctuate over time, particularly in individuals with moderately elevated concentrations, a UK Biobank analysis shows. People ...

Please provide your email address to receive an email when new articles are posted on . Lp(a) screening should be done once for all adults and high-risk children. Lp(a) level can help guide CVD risk ...

LPs invest capital and receive income, carrying no personal liability beyond their investment. GPs manage daily LP operations but face unlimited personal liability if the LP fails. LPs are taxed as ...